Table 1.
Overview of clinical and demographic characteristics
| Resting‐state fMRI study | Structural MRI study | |||||
|---|---|---|---|---|---|---|
| LID (n = 12) | No‐LID (n = 12) | P | LID (n = 14) | No‐LID (n = 14) | P | |
| Gender | 6f | 4f | >.5 | 7f | 5f | >.5 |
| Handedness | 10r | 11r | >.5 | 12r | 12r | >.5 |
| Age (y) | 66.8 ± 9.1 | 67.3 ± 6.8 | >.5 | 69.0 ± 10.0 | 64.2 ± 9.4 | >.1 |
| Education (y) | 14.1 ± 4.1 | 13.9 ± 3.5 | >.5 | 14.3 ± 4.0 | 13.2 ± 3.0 | >.1 |
| MMSE | 28.9 ± 1.8 | 29.6 ± 0.9 | >.1 | 28.9 ± 1.7 | 29.5 ± 0.9 | >.1 |
| MoCA | 27.8 ± 2.8 | 28.6 ± 1.1 | >.1 | 27.7 ± 2.6 | 28.7 ± 0.8 | >.1 |
| BIS‐11 | 59.3 ± 8.7 | 55.0 ± 7.7 | >.1 | 58.6 ± 8.3 | 57.1 ± 9.5 | >.5 |
| Disease duration (y) | 7.1 ± 3.8 | 5.9 ± 3.4 | >.1 | 8.0 ± 4.4 | 5.9 ± 3.4 | >.1 |
| LEDD (all) | 1014.9 ± 407 | 696.7 ± 252 | .031a | 958.9 ± 404 | 686.4 ± 268 | .045a |
| Levodopa (mg) | 848.9 ± 384 | 470.9 ± 228 | .008a | 810.9 ± 367 | 504.6 ± 288 | .021a |
| LEDD (no levodopa) | 166.0 ± 118 | 225.8 ± 138 | >.1 | 148.0 ± 119 | 181.8 ± 131 | >.1 |
| UPDRS‐III‐OFF | 32.2 ± 10.7 | 33.2 ± 6.9 | >.5 | 33.1 ± 10.4 | 33.2 ± 6.8 | >.5 |
| UPDRS‐III‐ON | 19.3 ± 7.1 | 21.3 ± 5.3 | >.1 | 20.4 ± 7.4 | 22.3 ± 4.1 | >.1 |
| Δ UPDRS‐III | 12.8 ± 5.2 | 11.9 ± 4 | >.5 | 12.7 ± 4.8 | 10.9 ± 4.1 | >.1 |
| UDysRS (obj.) | 14.2 ± 7.8 | ‐ | ‐ | 15.6 ± 8.3 | ‐ | ‐ |
Gender and handedness were compared using chi‐square tests. Age, education, MMSE, MOCA, Barratt Impulsiveness Scale (BIS), disease duration, levodopa equivalent daily dose (LEDD), and UPDRS were compared using independent‐sample t tests. obj., objective, f, female; r, right; y, years.
a
P uncorrected < .05.